Gilead Sciences | GILD - Sales Revenues

Stock Price
129.67
Daily Change
0.09 0.07%
Monthly
-4.56%
Yearly
22.15%
Q2 Forecast
126.98

Gilead Sciences reported $7B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
ALKERMES USD 392.91M 8.41M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
Biogen USD 2.25B 30M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eli Lilly USD 19.8B 500M Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
Incyte USD 1.27B 240M Mar/2026
J&J USD 24.1B 500M Mar/2026
Merck USD 16.29B 110M Mar/2026
Moderna USD 389M 289M Mar/2026
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
PTC Therapeutics USD 273M 108.3M Mar/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.24B 60M Mar/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
United Therapeutics USD 781.5M 8.7M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026